Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer

Anticancer Research

Volumn 30, Issue 1, 2010, Pages 233-238

  Aldulaymi, Bahir ^a   Christensen, Ib J ^b   Sölétormos, György ^a   Jess, Per ^a   Nielsen, Svend Erik ^a   Brünner, Nils ^c   Nielsen, Hans J ^c  

^a HILLERØD HOSPITAL   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CEA; Chemotherapy; Colon cancer; TIMP 1

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; BLOOD SAMPLING; CANCER STAGING; CANCER SURGERY; COLON CANCER; CONTINUOUS INFUSION; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 77649267967     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. O'Connell JB, Maggard MA and Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96(19): 1420-1425, 2004.
2. Eggington S et al: Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer 95(9): 1195-1201, 2006.
3. Wolpin BM and Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology 134(5): 1296-1310, 2008.
4. Andre T et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23): 2343-2351, 2004.
5. Locker GY et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24(33): 5313-5327, 2006.
6. Duffy MJ et al: Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43(9): 1348-1360, 2007.
7. Moller Sorensen N et al: Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 43(7): 774-786, 2008.
8. Chirco R et al: Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25(1): 99-113, 2006.
9. Holten-Andersen MN et al: Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 8(1): 156-164, 2002.
10. Waas ET et al: Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 48(4): 700-710, 2005.
11. Sorensen NM et al: TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 13(14): 4117-4122, 2007.
12. Holten-Andersen MN et al: Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Eur J Cancer 42(12): 1889-1896, 2006.
13. Frederiksen CB, Lomholt AF, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brünner N and Nielsen HJ: Changes in plasma TIMP-1 levels after resection for primary colorectal cancer. Anticancer Res 29: 75-82, 2009.
14. Wang JY et al: Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res 39(4): 245-250, 2007.
15. Sorbye H and Dahl O: Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines. J Clin Oncol 21(23): 4466-4467, 2003.
16. Ailawadhi S et al: Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology 70(1): 49-53, 2006.
17. Ohtsukasa S et al: Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. J Cancer Res Clin Oncol 129(12): 719-726, 2003.
18. Holten-Andersen MN et al: Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components. Scand J Clin Lab Invest 62(3): 223-230, 2002.
19. Holten-Andersen MN et al: Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer 113(2): 198-206, 2005.
20. Hammer JH et al: Impact of elective resection on plasma TIMP-1 levels in patients with colon cancer. Colorectal Dis 8(3): 168-172, 2006.
21. Bozec L et al: Irinotecan-induced immune thrombocytopenia. Ann Oncol 9(4): 453-455, 1998.
22. Stokes Z et al: Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer. Gynecol Oncol 97(3): 790-795, 2005.
23. Sorbye H, Bruserud Y and Dahl O: Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis. Acta Oncol 40(7): 882-883, 2001.
24. Koutras AK et al: Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 67(2): 179-182, 2004.
25. Curtis BR et al: Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 81(3): 193-198, 2006.
26. Guedez L et al: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102(11): 2002-2010, 1998.
27. Li G, Fridman R and Kim HR: Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59(24): 6267-6275, 1999.
28. Murphy FR et al: Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 277(13): 11069-11076, 2002.